These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 12932112)

  • 1. A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
    Fukumitsu N; Uchiyama M; Mori Y; Kishimoto K; Nakada J
    Ann Nucl Med; 2003 Jun; 17(4):297-303. PubMed ID: 12932112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of urine type I collagen-cross-linked N telopeptide levels with bone scintigraphic results in prostate cancer patients.
    Fukumitsu N; Uchiyama M; Mori Y; Yanada S; Hatano T; Igarashi H; Kishimoto K; Nakada J; Yoshihiro A; Harada J
    Metabolism; 2002 Jul; 51(7):814-8. PubMed ID: 12077723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y; Ochi M; Tokue A
    Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
    Akimoto S; Akakura K; Shimazaki J
    Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of the serum levels of bone formation and bone resorption markers in prostate cancer patients with bone metastasis.
    Akimoto S; Inomiya H; Furuya Y; Akakura K; Ito H
    Eur Urol; 1998 Aug; 34(2):142-7. PubMed ID: 9693250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collagen derived serum markers in carcinoma of the prostate.
    Rudnicki M; Jensen LT; Iversen P
    Scand J Urol Nephrol; 1995 Sep; 29(3):317-21. PubMed ID: 8578275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M; Noda S
    J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Studies of type I collagen related substances as bone metastatic markers of prostate carcinoma with special regard to serum carboxyterminal propeptide of type. I. Procollagen (PICP), cross-linked carboxyterminal telopeptide of type I collagen (ICTP) and Urinary deoxypyridinoline levels].
    Imai T; Honda M; Maeda S; Hosoya Y; Arai T; Sumi S; Umeda H; Yano M; Koga F; Arai K; Yoshida K
    Nihon Hinyokika Gakkai Zasshi; 1998 Apr; 89(4):484-91. PubMed ID: 9597867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer.
    Noguchi M; Yahara J; Noda S
    Urology; 2003 May; 61(5):993-8. PubMed ID: 12736022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of the carboxy-terminal propeptide of type I procollagen and the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as markers of bone metastases in patients with prostate carcinoma.
    Hosoya Y; Arai K; Honda M; Sumi S; Yoshida K
    Eur Urol; 1997; 31(2):220-3. PubMed ID: 9076470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients.
    Akimoto S; Okumura A; Fuse H
    Endocr J; 1998 Apr; 45(2):183-9. PubMed ID: 9700471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients.
    Zissimopoulos A; Bantis A; Stellos K; Petrakis G; Matthaios D
    J BUON; 2008; 13(1):69-74. PubMed ID: 18404790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis.
    Akimoto S; Furuya Y; Akakura K; Ito H
    Endocr J; 1998 Feb; 45(1):97-104. PubMed ID: 9625452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Serum concentration of pyridinoline cross-linked carboxy-terminal telopeptide of type-I collagen (ICTP) and carboxyterminal propeptide of human type I procollagen (PICP) in the diagnosis of bone metastases].
    Koizumi M; Yamada Y; Takiguchi T; Suzuki C; Akashi T; Nomura E; Yamashita T; Ogata E
    Kaku Igaku; 1996 Jan; 33(1):77-84. PubMed ID: 8819718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis: comparison with the extent of disease (EOD) grade.
    Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
    Prostate; 1999 Jan; 38(1):28-34. PubMed ID: 9973106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer.
    Westerhuis LW; Delaere KP
    Eur J Clin Chem Clin Biochem; 1997 Feb; 35(2):89-94. PubMed ID: 9056749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PICP as bone formation and NTx as bone resorption marker in patients with chronic renal failure.
    Franke S; Lehmann G; Abendroth K; Hein G; Stein G
    Eur J Med Res; 1998 Feb; 3(1-2):81-8. PubMed ID: 9512973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
    J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic value of urinary N-telopeptide of type I collagen in prostate cancer: comparison with bone scintigraphy].
    Fukumitsu N; Uchiyama M; Mori Y; Yanada S; Hatano T; Igarashi H; Nakada J
    Kaku Igaku; 1999 May; 36(4):333-9. PubMed ID: 10390956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.